Blogs

May 11, 2017
The challenges of data quality are a constant factor in clinical trials, especially that of traditional paper source documenting. Joyce Smith of The Medical Research Network speaks about the study’s site perspective on trial data quality.
May 11, 2017
Policy makers, sponsors and regulators are taking steps to promote alternative study formats and methods that go beyond randomized clinical trials.
May 10, 2017
Our series on patient centricity continues with a patient perspective on her interpretation of this subject. Shelly Hoover, an ALS patient, shares her views with Moe Alsumidaie.
May 09, 2017
Applied Clinical Trials
The Senate confirms Scott Gottlieb as FDA commissioner. User fee reauthorizations, a hiring freeze, and the opioid epidemic are a few of the issues awaiting the agency's new leader.
May 09, 2017
The EU’s national health organizations are contemplating to abandon their highly-prized autonomy, and forge common positions and buying strategies for accessing expensive new drugs.
May 09, 2017
Issues of counterfeit drugs being introduced into a supply chain have been a concern in comparative clinical trials. Terry Walsh of GSK speaks about the addressing this issue and ensuring that comparator drug supplies are more readily available for comparative trials.
May 02, 2017
As negotiations between the UK and the remaining 27 members of the European Union commence in the next month or so, questions of trade, IP protection and of free movement will emerge.
May 01, 2017
The recent partnership between Continuum Clinical and Lyft has introduced the convenience of transportation into the hands of patients. Nariman Nasser, VP of Site Optimization at Continuum Clinical, elaborates on this partnership.
Apr 25, 2017
At the end of April, European Immunization Week will take place celebrating the achievements of immunization in healthcare. However, contemporary sentiments of skepticism threaten to dampen the event.
Apr 24, 2017
As clinical trials remain costly and continue to increase, the promise of novel initiatives gives hope that trial duration and cost impact will drop. However, biopharma continues to overlook one element that affects study timelines: patient non-adherence.
native1_300x100
lorem ipsum